权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Detection of antiglycolipid antibody in the sera from the patients with autoimmune diseases

自身免疫性疾病患者血清中抗糖脂抗体的检测

基本信息

批准号：
62570298
负责人：
HIRANO Takao
金额：
$ 1.6万
依托单位：
Juntendo University
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (C)
财政年份：
1987
资助国家：
日本
起止时间：
1987 至 1989
项目状态：
已结题

项目摘要

A high incidence of autoantibody against glycolipid (asialo GM_1) antibody was observed in the sera from patients with neurological manifestations in 1980. At that time, we showed the existence of autoantibody against asialo GM1 by immunofloculation test. It has been greatly progressed in immunological method such as Enzyme Linked Immunosorbent assay (ELISA) and Then-layer chromatography (TLC) immunostaining for the detection of antibodies to glycolipids. The sera from 60 out of 102 cases of SLE with neurological disorders and 6 out of 10 patients with neuro-Behqet's disease showed antibody activity against asialo GM_1 but not against the asialo GM_2, GM_1 and galactocerebroside. In 7 out of 123 cases SLE having a history without neurological manifestations and out of 19 Behqet's patients without neurological disorders, antiasialo GM_1 antibody could be detectable.However, sera from patients with other autoimmune diseases, such as RA (60 cases) and PSS (32 cases) or from normal subjects did not show any antibody activity against asialo GM_1. Antiasialo GM_1 activities presents in both IgM and IgG immunoglobulin classes by class specific ELISA or TLC immilnostaining. Monoclonal antiasialo GM_1 antibodies were constructed in recently. We are attempting to detect glycolipid-antigen such as asialo GM_1 using monoclonal antibodies against glycolipids. These works are in progress in further more studies. The detection of antiglycolipid antibody may be useful in clinical diagnosis and these autoantibodies plays a important role in the pathogenesis of neurological manifestations with autoimmune diseases.

1980年在神经系统疾病患者血清中发现抗糖脂抗体（去唾液酸GM_1抗体）的高发生率。此时，我们通过免疫凝集试验证实了抗去唾液酸GM1自身抗体的存在。免疫学方法如酶联免疫吸附试验（ELISA）和薄层层析（TLC）免疫染色法检测糖脂抗体已取得了很大进展。102例SLE神经系统疾病患者中有60例和10例神经白塞病患者中有6例血清对去唾液酸GM_1有抗体活性，而对去唾液酸GM_2、GM_1和半乳糖苷无抗体活性。123例无神经系统疾病史的SLE患者中7例和19例无神经系统疾病史的Behqet病患者中7例可检测到抗去唾液酸GM_1抗体，而其他自身免疫性疾病如RA（60例）、PSS（32例）及正常人血清均未检测到抗去唾液酸GM_1抗体。用类特异性ELISA或TLC免疫组化法检测IgM和IgG类免疫球蛋白的抗去唾液酸GM_1活性。抗去唾液酸GM_1单克隆抗体是近年来研制成功的。我们正在尝试使用抗糖脂的单克隆抗体检测糖脂抗原，如去唾液酸GM_1。这些工作正在进一步的研究中进行。抗糖脂抗体的检测有助于临床诊断，这些自身抗体在自身免疫性疾病神经系统表现的发病机制中起重要作用。